2023 World Conference on Lung Cancer (Posters)-P1.21. Potential Role of Serum Glycoproteomics in Predicting irAEs in NSCLC Patients Treated with Immunotherapy

P1.21. Potential Role of Serum Glycoproteomics in Predicting irAEs in NSCLC Patients Treated with Immunotherapy - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the potential role of serum glycoproteomics in predicting immune-related adverse events (irAEs) in patients with non-small cell lung cancer (NSCLC) treated with immunotherapy. The researchers analyzed pretreatment blood samples from 47 NSCLC patients who were treated with an immune checkpoint inhibitor (ICI). The samples were interrogated using liquid chromatography and mass spectrometry with an artificial intelligence-based data processing engine. They identified 22 glycopeptides that showed a statistically significant difference between patients with and without irAEs. These 22 glycopeptides were used as a glycoproteomics signature to cluster the patients into two groups. The researchers found that the proportion of patients with irAEs was higher in one of the clusters. Furthermore, there was a statistically significant difference in the development of the first irAE between the two clusters. However, the glycoproteomics signature did not predict the response or survival to ICI treatment. <br /><br />The findings suggest that there are differences in patterns of glycoproteomics between NSCLC patients with and without irAEs. The researchers propose that incorporating glycoproteomics as a biomarker could potentially help predict the development of irAEs in patients undergoing immunotherapy. However, further validation with a larger cohort is needed to confirm these findings. This study highlights the importance of considering host factors in predicting and monitoring irAEs in immunotherapy-treated patients.

Asset Subtitle

Young Kwang Chae

Meta Tag

Speaker Young Kwang Chae

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

serum glycoproteomics

immune-related adverse events

non-small cell lung cancer

immunotherapy

pretreatment blood samples

immune checkpoint inhibitor

liquid chromatography

mass spectrometry

artificial intelligence-based data processing engine

glycopeptides signature